Metoprolol is a beta-adrenergic blocker sold in the U.S. under 5 brand and generic names, for angina pectoris, atrial fibrillation and atrial flutter. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Kapspargo Sprinkle (application NDA210428). Other metoprolol products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Adult Hypertension: Usual initial dosage is 25 to 100 mg once daily. Titrate weekly (or longer) to optimal blood pressure. (2.1) • Pediatric Hypertension 6 years of age and older: The recommended starting dose is 1 mg/kg, once daily and titrate to response. Do not exceed a maximum initial dose of 50 mg once daily. (2.1) • Angina Pectoris: Usual initial dosage is 100 mg once daily. Titrate weekly based on clinical response. (2.2) • Heart Failure: The recommended starting dose is 25 mg doubled every two weeks to the highest dose tolerated or up to 200 mg. (2.3) 2.1 Hypertension Adults: The usual initial dosage is 25 mg to 100 mg once daily in a single dose. Adjust dosage at weekly (or longer) intervals until optimum blood pressure reduction is achieved. Dosages above 400 mg per day have not been studied. Pediatric Hypertensive Patients 6 Years of age or older: The recommended starting dose of metoprolol succinate extended-release capsules is 1 mg/kg once daily, the maximum initial dose should not exceed 50 mg once daily. Adjust dosage according to blood pressure response. Doses above 2 mg/kg (or in excess of 200 mg) once daily have not been studied in pediatric patients [see Clinical Pharmacology (12.3)]. Metoprolol succinate extended-release capsules has not been studied in pediatric patients less than 6 years of age [see Use in Specific…
The following adverse reactions are described elsewhere in labeling: • Worsening angina or myocardial infarction. [see Warnings and Precautions (5)] • Worsening heart failure. [see Warnings and Precautions (5)] • Worsening AV block. [see Contraindications (4)] • Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. Hypertension and Angina: Most adverse reactions have been mild and transient. The most common (>2%) adverse reactions are tiredness, dizziness, depression, diarrhea, shortness of breath, bradycardia, and rash. Heart Failure: In the MERIT-HF study comparing metoprolol succinate in daily doses up to 200 mg (mean dose 159 mg once-daily; n=1990) to placebo…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 54/100 | Prescription | Injectable | Generic | $1 | View → | |
| 2 | Not yet rated | Prescription | Capsule | Generic | $1 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| R25 | 25 mg | pink | round | — |
| e701 | 100 mg | white | round | — |
| R50 | 50 mg | pink | round | — |
| R50 | 50 mg | pink | round | — |
| L;151 | 50 mg | pink | round | — |
| 5;67 | 200 mg | white |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Ascend Laboratories
Failed Dissolution Specifications
Ascend Laboratories, LLC · Apr 27, 2026
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Jan 29, 2026
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Jan 29, 2026
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Jan 29, 2026
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
Teva Pharmaceuticals USA, Inc · Jan 29, 2026
The elimination half-life of metoprolol is about 3 to 4 hours. This is for immediate-release metoprolol tartrate; the half-life is longer (about 7 to 9 hours) in the roughly 8% of people who are poor CYP2D6 metabolizers, so it varies with how a person metabolizes the drug. Metoprolol's metabolites have no meaningful beta-blocking activity, so no active metabolite extends the effect.
Metoprolol Tartrate tablet, film coated — DailyMed ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Metoprolol succinate is contraindicated in severe bradycardia, second or third degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. • Known hypersensitivity to product components. (4) • Severe bradycardia, greater than first degree heart block, or sick sinus syndrome without a pacemaker. (4) • Cardiogenic shock or decompensated heart failure. (4)
Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. (7.1) • Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (7.2) • CYP2D6 Inhibitors are likely to increase metoprolol concentration. (7.3) • Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. (7.4) • Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. (7.4) • Alcohol interferes with the extended release properties of this product. (7.5) 7.1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 Epinephrine While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat an allergic reaction. 7.3 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6, such as quinidine, fluoxetine, paroxetine,…
| View → |
| 3 | Not yet rated | Prescription | Solution | Generic | $1 | View → |
| 4 | Not yet rated | Prescription | Capsule | Generic | $1 | View → |
| 5 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
| oval |
| — |
| C;L;407 | 50 mg | white | round | — |
|---|
| 566 | 100 mg | white | round | — |
|---|
| 5;67 | 200 mg | white | oval | — |
|---|